학술논문

A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer
Document Type
Journal
Source
ANNALS OF ONCOLOGY; AUG 2023, 34 8, p714-p722, 9p.
Subject
Language
English
ISSN
15698041